# Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal

> **NCT03064035** · PHASE4 · COMPLETED · sponsor: **HealthPartners Institute** · enrollment: 79 (actual)

## Conditions studied

- Acute Bleeding on Long-Term Anticoagulation Therapy
- Hemorrhage
- Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time)
- Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation

## Interventions

- **DRUG:** 4-factor prothrombin complex concentrate (4FPCC)

## Key facts

- **NCT ID:** NCT03064035
- **Lead sponsor:** HealthPartners Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-05
- **Primary completion:** 2019-04-17
- **Final completion:** 2019-04-24
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03064035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03064035, "Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03064035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*